Health

Cannabix Technologies announces Non-Brokered LIFE Private Placement

February 06, 2026 19:00 ET  | Source: Cannabix Technologies Inc.   NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR…

2 weeks ago

LuminEye Nano-Drops Product Information Updated as Consumer Interest in Eye Health Supplement Options and Vision Support Alternatives Grows in 2026

New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not…

2 weeks ago

HUTCHMED to Announce 2025 Final Results

February 06, 2026 03:30 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06,…

2 weeks ago

VALNEVA Declaration of shares and voting rights: January 31, 2026

VALNEVA Declaration of shares and voting rights January 31, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât.…

2 weeks ago

Coloplast A/S – Interim Financial Report, Q1 2025/26

2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT…

2 weeks ago

Pluristyx and Solesis Launch First-of-its-Kind PluriForm-GFP-3D Transfection Kit, Solving Critical Bottlenecks in Suspension Culture Transfection

New ready-to-use kit combines Pluristyx’s high-quality pluripotent cells and mRNA technology with Solesis’ proprietary transfection technology to achieve nearly 100%…

2 weeks ago

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

February 05, 2026 07:01 ET  | Source: BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) --…

2 weeks ago

Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 05, 2026 07:00 ET  | Source: Dianthus Therapeutics, Inc. NEW YORK and WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE)…

2 weeks ago

Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer

DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation from FDAClinical entry validates condensate modulator…

2 weeks ago

Novo Nordisk files annual report with the SEC

Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its Annual Report 2025 on Form 20-F for the…

2 weeks ago